Comparison of gastrointestinal adverse effects between cyclooxygenase-2(COX-2) inhibitors and non-selective, non-steroidal anti-inflammatory drugs (ns-NSAID) plus proton pump inhibitors (PPI) '' [1]. According to our analyses, the risk of major gastrointestinal (GI) complications was lower in COX-2 inhibitors, as compared to ns-NSAIDs plus PPI. We agree that patients who take COX-2 inhibitors are still at risk for GI adverse events, when compared to patients who do not take these medications. As shown in a metaanalysis by Rostrom et al.
To the Editor:
We thank Dr. Lai and his colleagues for their comments related to our article ''Comparison of gastrointestinal adverse effects between cyclooxygenase-2(COX-2) inhibitors and non-selective, non-steroidal anti-inflammatory drugs (ns-NSAID) plus proton pump inhibitors (PPI)'' [1] . According to our analyses, the risk of major gastrointestinal (GI) complications was lower in COX-2 inhibitors, as compared to ns-NSAIDs plus PPI. We agree that patients who take COX-2 inhibitors are still at risk for GI adverse events, when compared to patients who do not take these medications. As shown in a metaanalysis by Rostrom et al. [2] , high-dose COX-2 inhibitors insignificantly increased the risk of gastric (relative risk or RR 1.22; 95% CI 0.83-1.80) and duodenal (RR, 1.29; 95% CI 0.63-2.66) ulcers, as compared to placebo. However, when compared to ns-NSAIDs, the risk of major GI complications including perforation, ulceration, bleeding, and obstruction were lower in COX-2 inhibitors.
The increased risk of peptic ulcer in a cohort study needs to be cautiously interpreted because this study design is susceptible to selection bias resulting in imbalanced prognostic characteristics at baseline. In daily practice, physicians usually prescribe COX-2 inhibitors for patients who are at high risk of developing GI complications, e.g., old age, prior GI ulcer or bleeding, aspirin or anti-coagulant user, and steroid use, whereas patients with low risk are usually treated with ns-NSAIDs. Therefore, the risk of GI complications between COX-2 inhibitors vs. ns-NSAIDs may be comparable or even higher in COX-2 inhibitors.
We totally agree that COX-2 inhibitors are associated with increased risk of GI complication. Patients requiring NSAID therapy who are at high risk should receive COX-2 inhibitor and GI protective therapy (e.g., misoprostol or PPI) or alternative therapy for pain control.
